ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Sight Sciences Inc

Sight Sciences Inc (SGHT)

6.38
0.02
(0.31%)
Closed June 22 4:00PM
6.35
-0.03
(-0.47%)
After Hours: 7:59PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
6.38
Bid
4.00
Ask
7.50
Volume
205,061
6.30 Day's Range 6.51
1.04 52 Week Range 9.3075
Market Cap
Previous Close
6.36
Open
6.39
Last Trade Time
Financial Volume
$ 1,309,864
VWAP
6.3877
Average Volume (3m)
157,710
Shares Outstanding
49,756,252
Dividend Yield
-
PE Ratio
-5.69
Earnings Per Share (EPS)
-1.12
Revenue
81.06M
Net Profit
-55.55M

About Sight Sciences Inc

Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilit... Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. Its Surgical Glaucoma segment's product portfolio features the OMNI Surgical System, a device that facilitates the performance of both canaloplasty and trabeculotomy with a single device and single corneal incision to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The company's Dry Eye segment's product portfolio consists of the TearCare System for ophthalmologists and optometrists. It derives key revenue from the Surgical Glaucoma segment. Show more

Sector
Surgical,med Instr,apparatus
Industry
Surgical,med Instr,apparatus
Headquarters
Dover, Delaware, USA
Founded
1970
Sight Sciences Inc is listed in the Surgical,med Instr,apparatus sector of the NASDAQ with ticker SGHT. The last closing price for Sight Sciences was $6.36. Over the last year, Sight Sciences shares have traded in a share price range of $ 1.04 to $ 9.3075.

Sight Sciences currently has 49,756,252 shares outstanding. The market capitalization of Sight Sciences is $315.95 million. Sight Sciences has a price to earnings ratio (PE ratio) of -5.69.

SGHT Latest News

Sight Sciences Announces the Release of its First Sustainability Report

MENLO PARK, Calif., June 10, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...

Sight Sciences Announces the Publication of Twelve-Month Results of the SAHARA RCT Demonstrating Improved Signs and Symptoms of Dry Eye Disease for TearCare Patients Crossed Over from Restasis

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and...

Sight Sciences Announces Publication of a New Analysis from The ROMEO Study Showing Meaningful Pressure and Medication Reductions Achieved with OMNI® Across Mild, Moderate, and Advanced Glaucoma

MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.38-5.621301775156.766.886.3908706.45501051CS
41.0920.60491493385.297.43995.291277256.61943283CS
121.0820.37735849065.37.43994.881577105.79686725CS
262.983.33333333333.487.43993.122942245.29344147CS
52-1.81-22.10012210018.199.30751.043115094.27459764CS
156-23.62-78.73333333333042.571.0426186911.27318059CS
260-23.62-78.73333333333042.571.0426186911.27318059CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

SGHT Discussion

View Posts
Monksdream Monksdream 7 days ago
SGHT under $10
👍️0
Southern Gal Southern Gal 2 weeks ago
Wow- somebody took a bunch of profit in the last minutes. First down day is quite a while
👍️0
Southern Gal Southern Gal 2 weeks ago
And another up day.
👍️0
Southern Gal Southern Gal 2 weeks ago
First time SGHT closed above $7 in over 6 months!!!
👍️0
Southern Gal Southern Gal 3 weeks ago
She broke through seven dollars. very strong volume today. So bright I gotta wear shades
👍️0
Southern Gal Southern Gal 3 weeks ago
Good news...

creates big gains. Blue skies ahead. My $2.98's have doubled+
👍️0
Southern Gal Southern Gal 3 weeks ago
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) (“Sight Sciences,” or the “Company”), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients’ lives, today announced the publication of the twelve-month results from the SAHARA trial.

Patients previously treated with Restasis® (cyclosporine ophthalmic emulsion 0.05%) prescription eyedrops (“Restasis”) had additional clinically meaningful improvements in the signs and symptoms of dry eye disease (“DED”) when crossed over to TearCare. These improvements persisted for six months through month twelve without continued Restasis use.

“Phase 2 of the RCT again demonstrates the clinical effectiveness of TearCare. It also shows that effectiveness appears to be the same whether or not a patient has had prior treatment with Restasis, demonstrating that similar results could be expected when TearCare is used as a primary or secondary treatment for DED,” said Paul Badawi, Co-Founder and Chief Executive Officer of Sight Sciences.

Phase 1 of the SAHARA RCT included 345 subjects at 19 sites in 11 states randomized 1:1 to either TearCare or Restasis1. In Phase 2 of the SAHARA RCT, 163 patients who had been randomized and treated with Restasis during phase 1 were crossed over to TearCare at the six-month visit and followed for six months through Month 12 of the study.

Data from the first six months of the SAHARA RCT demonstrated that TearCare, an interventional eyelid procedure for DED, was superior at all measured time points to twice daily use of Restasis for the improvement of tear break up time (“TBUT”), the trial’s primary dry eye signs endpoint and a key measure of tear stability1. TearCare was superior to Restasis in multiple other objective measures of dry eye, and demonstrated clinically meaningful improvements in several symptoms that matched or surpassed Restasis at all measured time points.

The aim of phase 2, undertaken in months six through twelve, was to demonstrate that cessation of Restasis followed by a single TearCare procedure would result in improved signs and symptoms for patients beyond what was achieved with six months of Restasis.
👍️0
Southern Gal Southern Gal 4 weeks ago
MENLO PARK, Calif., May 28, 2024 (GLOBE NEWSWIRE) -- Sight Sciences, Inc. (Nasdaq: SGHT) ("Sight Sciences" or the "Company"), an eyecare technology company focused on developing and commercializing innovative, interventional technologies intended to transform care and improve patients' lives, today announced the results as published in the journal Clinical Ophthalmology of a new analysis of the ROMEO (Retrospective, Observational, Multicenter Evaluation of OMNI) study data. This new analysis evaluated the association between the severity of glaucoma and the intraocular pressure ("IOP") and medication outcomes for patients treated with the OMNI Surgical System ("OMNI"). OMNI enables a procedure intended to restore aqueous outflow of glaucomatous eyes by addressing the three areas of outflow resistance associated with the disease.

The findings suggest that ab interno canaloplasty coupled with trabeculotomy using OMNI was as effective at lowering IOP and reducing medication usage in advanced glaucoma patients as it was in mild and moderate glaucoma patients. This data challenges the belief that advanced disease stage is a barrier to successful treatment outcomes for minimally invasive glaucoma surgery ("MIGS").

"There had been some debate about the efficacy of MIGS in advanced glaucoma patients, with speculation that prolonged disease may cause irreversible harm to the distal outflow pathway," said Dr. Jaime E. Dickerson, Jr., Vice President of Medical and Clinical Affairs at Sight Sciences. "The current study suggests that treatment with OMNI technology, which has a strong safety profile and proven durability, is still effective in patients with more extensive visual field damage."

ROMEO was an Institutional Review Board ("IRB") approved retrospective case series conducted at eleven ophthalmology practices in the United States. Participants were mainly primary open-angle glaucoma patients (122 of 129, or 95%) who had undergone the implant-free OMNI procedure, which has been cleared by the FDA for canaloplasty followed by ab interno trabeculotomy to reduce intraocular pressure in adult patients with primary open-angle glaucoma, either combined with cataract surgery or as a standalone procedure.

Eyes were categorized based on visual field mean deviation ("MD"), with participants assigned to a group with severity rated as mild (n=79, median MD -2.7 dB), moderate (n=42, median MD -8.0 dB) or advanced (n=6, median MD -13.3). The study compared outcomes at 12 months.

Key findings reported in the study include:

Significant reductions in both IOP and IOP-reducing medications were observed.
The majority of eyes (70%) experienced a reduction in IOP at Month 12, with most achieving levels of 18 mmHg or less (92%).
The percentage of IOP reduction was consistent across severity groups, with month 12 mean IOP ranging between 14 mmHg and 16 mmHg.
Medication reductions were observed across all severity groups, with the majority of patients showing a reduction of at least 1 medication (50% to 69%), indicating the effectiveness of the treatment approach.
Regression analysis found no significant relationship between month 12 IOP and visual field loss, suggesting treatment outcomes were consistent irrespective of disease severity.
"Clinical trials and real-world results continue to demonstrate favorable OMNI treatment outcomes across different stages of glaucoma," said Paul Badawi, Co-Founder and CEO of Sight Sciences. "These findings reinforce our dedication to offering effective treatment options for glaucoma patients at every stage of the disease and also fuel our initiatives to continue reimagining eyecare with transformative technology and an interventional mindset."
👍️0
Southern Gal Southern Gal 2 months ago
Looking awesome! Excellent quarterly conference call. PPS is strong and the future should be most favorable. +$6 is a few pennies away. +$10 this summer seems reasonable.
👍️0
Southern Gal Southern Gal 2 months ago
Great news!
👍️0
Southern Gal Southern Gal 2 months ago
News of a settlement? Basis for yesterday's gain?
04/23/2024 STATEMENT Offer of Proof Regarding the Economic Comparability of the Glaukos Settlement Agreement by Alcon Inc.,
👍️0
Southern Gal Southern Gal 2 months ago
Beautiful close above $6.
👍️0
Southern Gal Southern Gal 2 months ago
Jury selection begins pretty soon between Alcon and sight sciences. SGHT has very good sales and clinically proven efficacy. Seems to me that the quickest fix for Alcon’s problems is to buy sight sciences, lock, stock, and barrel. Alcon gets two great products and whatever sight sciences has in development. Perhaps most importantly, an acquisition makes Alcon's legal problems go away. Alcon's is looking at huge retroactive and ongoing royalties due to Sight Sciences, if the jury decides against Alcon.
👍️0
Invest-in-America Invest-in-America 3 months ago
SGHT: The potential expansive applications for their tech. go way beyond mere 'DRY EYES', per se.
👍️0
Invest-in-America Invest-in-America 3 months ago
SGHT: We'll see what their 'Industry' thinks about it come 4-5-24. (Their Firm is in Menlo Park --- i.e., "Silicon Valley".)
👍️0
Southern Gal Southern Gal 3 months ago
“Long-term data is key in the selection of a surgical treatment,” said Arkadiy Yadgarov, MD, of Omni Eye Services of Atlanta, GA. “The 12-month GEMINI trial demonstrated efficacy of the OMNI procedure combined with cataract surgery for IOP and medication reduction in mild-to-moderate glaucoma.1,2 This extension of the trial shows that these positive 12-month outcomes were sustained through 36 months.”

👍️0
Southern Gal Southern Gal 3 months ago
“In phase 1 of the SAHARA trial, we found the interventional TearCare procedure provided statistically superior and sustained improvement in tear break-up time and multiple measures of meibomian gland secretion when compared to treatment with Restasis.3 In phase 2 (cross-over) of the study, we found that a single TearCare procedure improved signs and symptoms for patients beyond what was achieved with six months of Restasis.”
👍️0
Invest-in-America Invest-in-America 3 months ago
SGHT: (See their PR, below) Their CEO seems pretty excited about their looming presentation to fix Dry Eye disorder, inter alia.
https://finance.yahoo.com/news/sight-sciences-announces-results-three-200500426.html
👍️0
Southern Gal Southern Gal 3 months ago
Up huge after hours following good news
Can’t wait for tomorrow morning.
👍️0
Southern Gal Southern Gal 3 months ago
Up again
👍️0
Southern Gal Southern Gal 3 months ago
Looking strong. $5
👍️0
Southern Gal Southern Gal 4 months ago
Q will be discussed early March. Now that reimbursement is no longer an issue, blue sky ahead.
👍️0
Dubster watching Dubster watching 4 months ago
Well done sister! Gl
👍️0
Southern Gal Southern Gal 4 months ago
Bought more near $4
👍️0
Dubster watching Dubster watching 5 months ago
Thoughts?
Ill wait this time to see what you think.
Im not feeling it yet on this.
👍️0
DollarDan DollarDan 5 months ago
Walk away while you can!
👍️0
Southern Gal Southern Gal 5 months ago
good for you!
I'm holding my 68,000 shares for higher gains.
I wish I put in the same money when I bought shares near $1

68110 shares at $2.98/share

Day Gain
+$55,850.18(+15.92%)
Total Gain
+$203,648.89(+100.34%)
👍️0
Dubster watching Dubster watching 5 months ago
I couldn’t resist.
GL
👍️0
Dubster watching Dubster watching 5 months ago
Sold $5.93
👍️0
Southern Gal Southern Gal 5 months ago
Waiting for news to explain today's big jump.
Going to break $6?
👍️0
Dubster watching Dubster watching 5 months ago
Nice green start to this!
👍️0
Dubster watching Dubster watching 5 months ago
$5.10 loaded
👍️0
Dubster watching Dubster watching 5 months ago
Thoughts on current price?
I have a low bid sitting but you watch this better than I do.
👍️0
Southern Gal Southern Gal 5 months ago
Another good year. I wonder if Q4 showed a downturn due to the possibility of Medicare declining to reimburse. Now that Medicare has confirmed reimbursement I suspect Q1 and beyond will be strong.


https://finance.yahoo.com/news/sight-sciences-announces-preliminary-unaudited-210500004.html
👍️0
Dubster watching Dubster watching 6 months ago
You deserve it!
👍️0
Southern Gal Southern Gal 6 months ago
What an awesome day. Massive volume and up 55%
👍️0
Southern Gal Southern Gal 6 months ago
Big vol and gain. Happy Holidays!
👍️0
Southern Gal Southern Gal 6 months ago
Looking for reversals of mac notifications
👍️0
Southern Gal Southern Gal 6 months ago
MORE GOOD NEWS

https://finance.yahoo.com/news/sight-sciences-announces-publication-successful-210500987.html
👍️0
Southern Gal Southern Gal 6 months ago
Better than 8% up today. New study will resolve reimbursement issues.

https://www.dovepress.com/36-month-outcomes-from-the-prospective-gemini-study-canaloplasty-and-t-peer-reviewed-fulltext-article-OPTH
👍️0
Southern Gal Southern Gal 7 months ago
Up .20 premarket

Staffan Encrantz, an insider of Sight Sciences, Inc., recently acquired 521,855 shares of the company. The buys took place at prices ranging from $3.09 to $3.46 per share, on dates ranging from November 24 to November 28, 2023. Encrantz now owns 6,074,526
👍️0
Southern Gal Southern Gal 7 months ago
I bought back in today.
👍️0
Southern Gal Southern Gal 7 months ago
I'm all out @ $2

Good luck to those who wait for even greener pastures
👍️0
Southern Gal Southern Gal 7 months ago
$2.11 SWEET

About doubled on my latest buys
👍️0
Southern Gal Southern Gal 8 months ago
Up .13 today
Up .05 after hours
👍️0
Dubster watching Dubster watching 8 months ago
Well done.
I jumped on too soon but saw a bit of green on the way out.
👍️0
Southern Gal Southern Gal 8 months ago
Currently $1.65

Nice recovery from my $1.07 buys
👍️0
Dubster watching Dubster watching 8 months ago
Finally saw the GREEN and dumped 85% of my shares +1.9%
Wild ride
👍️0
Dubster watching Dubster watching 8 months ago
I doubled down $1.35but still need to make up 3%
Good job!
👍️0
Southern Gal Southern Gal 8 months ago
Nice bounce, as I predicted
👍️0

Your Recent History

Delayed Upgrade Clock